Ken Griffin Rocket Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,000 shares of RCKT stock, worth $270,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,000

Previous 20,300 13.3%

Holding current value

$270,250

Previous $437,000 2.97%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$17.6 - $25.88 $11.8 Million - $17.3 Million	-669,976 Reduced 23.77%	2,148,093 $39.7 Million
Q2 2024 Aug 14, 2024	BUY	$20.66 - $26.72 $7.19 Million - $9.31 Million	348,256 Added 14.1%	2,818,069 $60.7 Million
Q1 2024 May 15, 2024	BUY	$26.16 - $30.74 $320,512 - $376,626	12,252 Added 0.5%	2,469,813 $66.5 Million
Q4 2023 Feb 14, 2024	SELL	$16.78 - $31.94 $3.71 Million - $7.06 Million	-220,940 Reduced 8.25%	2,457,561 $73.7 Million
Q3 2023 Nov 14, 2023	BUY	$15.07 - $24.05 $1.36 Million - $2.17 Million	90,393 Added 3.49%	2,678,501 $54.9 Million
Q2 2023 Aug 14, 2023	SELL	$16.59 - $23.6 $1.18 Million - $1.67 Million	-70,841 Reduced 2.66%	2,588,108 $51.4 Million
Q1 2023 May 15, 2023	BUY	$15.79 - $22.6 $888,487 - $1.27 Million	56,269 Added 2.16%	2,658,949 $45.5 Million
Q4 2022 Feb 14, 2023	BUY	$15.5 - $22.76 $13 Million - $19.1 Million	838,759 Added 47.55%	2,602,680 $50.9 Million
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $3.17 Million - $4.71 Million	256,082 Added 16.98%	1,763,921 $28.2 Million
Q2 2022 Aug 15, 2022	SELL	$7.96 - $16.64 $2.22 Million - $4.63 Million	-278,416 Reduced 15.59%	1,507,839 $20.7 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $23.68 $1.23 Million - $2.21 Million	93,289 Added 5.51%	1,786,255 $28.3 Million
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $8.48 Million - $14.2 Million	393,990 Added 30.33%	1,692,966 $37 Million
Q3 2021 Nov 15, 2021	BUY	$27.42 - $48.97 $13.7 Million - $24.5 Million	501,297 Added 62.84%	1,298,976 $38.8 Million
Q2 2021 Aug 16, 2021	BUY	$39.41 - $47.25 $4.37 Million - $5.24 Million	110,881 Added 16.14%	797,679 $35.3 Million
Q1 2021 May 17, 2021	SELL	$43.34 - $65.91 $27.4 Million - $41.7 Million	-632,105 Reduced 47.93%	686,798 $30.5 Million
Q4 2020 Feb 16, 2021	BUY	$23.3 - $59.57 $4.83 Million - $12.3 Million	207,094 Added 18.63%	1,318,903 $72.3 Million
Q3 2020 Nov 16, 2020	BUY	$20.5 - $28.59 $781,152 - $1.09 Million	38,105 Added 3.55%	1,111,809 $25.4 Million
Q2 2020 Aug 14, 2020	BUY	$13.32 - $22.61 $103,030 - $174,888	7,735 Added 0.73%	1,073,704 $22.5 Million
Q1 2020 May 15, 2020	SELL	$9.71 - $25.11 $1.69 Million - $4.36 Million	-173,689 Reduced 14.01%	1,065,969 $14.9 Million
Q4 2019 Feb 14, 2020	BUY	$11.07 - $24.23 $514,278 - $1.13 Million	46,457 Added 3.89%	1,239,658 $28.2 Million
Q3 2019 Nov 14, 2019	BUY	$10.85 - $14.78 $857,508 - $1.17 Million	79,033 Added 7.09%	1,193,201 $13.9 Million
Q2 2019 Aug 14, 2019	BUY	$15.0 - $19.81 $265,410 - $350,518	17,694 Added 1.61%	1,114,168 $16.7 Million
Q1 2019 May 15, 2019	BUY	$13.45 - $19.01 $218,118 - $308,285	16,217 Added 1.5%	1,096,474 $0
Q4 2018 Feb 14, 2019	BUY	$11.21 - $23.53 $3.61 Million - $7.58 Million	322,211 Added 42.51%	1,080,257 $16 Million
Q3 2018 Nov 13, 2018	SELL	$18.5 - $25.49 $1.31 Million - $1.81 Million	-71,020 Reduced 8.57%	758,046 $0
Q2 2018 Aug 10, 2018	BUY	$14.58 - $23.0 $5.97 Million - $9.42 Million	409,564 Added 97.63%	829,066 $0
Q1 2018 May 11, 2018	BUY	$11.68 - $19.19 $4.9 Million - $8.05 Million	419,502 New	419,502 $7.87 Million

Others Institutions Holding RCKT

# of Institutions

209

Shares Held

93.2M

Call Options Held

319K

Put Options Held

70.3K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $889M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account